Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection.

@article{Kfoury2009CardiovascularMA,
  title={Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection.},
  author={Abdallah Kfoury and M Elizabeth Hale Hammond and Gregory L. Snow and Stavros G. Drakos and Josef Stehlik and Patrick W Fisher and Bruce B. Reid and Melanie D Everitt and Feras M Bader and Dale G. Renlund},
  journal={The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation},
  year={2009},
  volume={28 8},
  pages={781-4}
}
BACKGROUND Little has been reported on the clinical significance of asymptomatic antibody-mediated rejection (AMR) alone or mixed rejection (MR), defined as concurrent cellular rejection (CR) and AMR in heart transplantation. In this study, we examined whether a differential impact on cardiovascular mortality (CVM) existed when comparing asymptomatic AMR, to stable MR or CR. METHODS The Utah Transplantation Affiliated Hospitals (UTAH) Cardiac Transplant Program pathology database of all heart… CONTINUE READING